Assessing the Health Economic Outcomes from Commercially Insured Relapsing Multiple Sclerosis Patients Who Switched from Other Disease-Modifying Therapies to Teriflunomide, in the United States

Araujo L, Kyatham S, Bzdek KG, Higuchi K, Greene N

ClinicoEconomics and Outcomes Research 2023, 15:361-373

Published Date: 20 May 2023